Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

South Korea: These 53 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "South Korea: These 53 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can AXUMIN (fluciclovine f-18) generic drug versions launch in South Korea?

Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: South Korea Patent 101,608,755

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. Additional details are available on the fluciclovine f-18 profile page.

When can ZTALMY (ganaxolone) generic drug versions launch in South Korea?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: South Korea Patent 101,405,545

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can ZTALMY (ganaxolone) generic drug versions launch in South Korea?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: South Korea Patent 101,415,329

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can ZTALMY (ganaxolone) generic drug versions launch in South Korea?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: South Korea Patent 20,120,107,533
Patent Title: GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can ZTALMY (ganaxolone) generic drug versions launch in South Korea?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: South Korea Patent 20,130,123,471
Patent Title: GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in South Korea?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: South Korea Patent 101,514,700

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in South Korea?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: South Korea Patent 20,090,087,020
Patent Title: (알파 S, 베타 R)―6―브로모―알파―[2―(디메틸아미노)에틸]―2―메톡시―알파―1―나프탈레닐―베타―페닐―3―퀴놀린에탄올의 푸마레이트 염 (FUMARATE SALT OF ALPHA S BETA R-6-BROMO-ALPHA-[2-DIMETHYLAMINOETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINEETHANOL)

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in South Korea?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: South Korea Patent 101,174,201

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in South Korea?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: South Korea Patent 101,364,277

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in South Korea?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: South Korea Patent 20,100,050,557

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in South Korea?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: South Korea Patent 20,110,117,195

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in South Korea?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: South Korea Patent 101,464,391

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in South Korea?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: South Korea Patent 20,090,087,916
Patent Title: 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in South Korea?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: South Korea Patent 101,451,993

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in South Korea?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: South Korea Patent 101,593,579

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in South Korea?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: South Korea Patent 20,140,088,617
Patent Title: THERAPEUTIC COMPOSITIONS

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in South Korea?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: South Korea Patent 101,436,303

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in South Korea?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: South Korea Patent 20,090,121,291
Patent Title: METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in South Korea?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: South Korea Patent 101,486,091

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in South Korea?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: South Korea Patent 20,090,109,115

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can LEXISCAN (regadenoson) generic drug versions launch in South Korea?

Generic name: regadenoson
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 02, 2027
Generic Entry Controlled by: South Korea Patent 20,080,090,491
Patent Title: PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS

LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LEXISCAN

See drug price trends for LEXISCAN.

The generic ingredient in LEXISCAN is regadenoson. Additional details are available on the regadenoson profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 101,670,016

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 101,837,010

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 20,150,038,322
Patent Title: 안정한 소화 효소 조성물 (Stable digestive enzyme compositions)

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 101,670,016

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 101,837,010

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in South Korea?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: South Korea Patent 20,150,038,322
Patent Title: 안정한 소화 효소 조성물 (Stable digestive enzyme compositions)

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can DYANAVEL XR (amphetamine) generic drug versions launch in South Korea?

Generic name: amphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: South Korea Patent 101,495,146

Drug Price Trends for DYANAVEL XR
DYANAVEL XR is a drug marketed by Tris Pharma Inc. There are twelve patents protecting this drug. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering DYANAVEL XR

See drug price trends for DYANAVEL XR.

The generic ingredient in DYANAVEL XR is amphetamine. Additional details are available on the amphetamine profile page.

When can TUZISTRA XR (chlorpheniramine polistirex; codeine polistirex) generic drug versions launch in South Korea?

Generic name: chlorpheniramine polistirex; codeine polistirex
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: South Korea Patent 101,495,146

TUZISTRA XR is a drug marketed by Tris Pharma Inc. There are two patents protecting this drug. There has been litigation on patents covering TUZISTRA XR

See drug price trends for TUZISTRA XR.

The generic ingredient in TUZISTRA XR is chlorpheniramine polistirex; codeine polistirex. Additional details are available on the chlorpheniramine polistirex; codeine polistirex profile page.

When can VANFLYTA (quizartinib dihydrochloride) generic drug versions launch in South Korea?

Generic name: quizartinib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2027
Generic Entry Controlled by: South Korea Patent 101,549,364

VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.

See drug price trends for VANFLYTA.

The generic ingredient in VANFLYTA is quizartinib dihydrochloride. Additional details are available on the quizartinib dihydrochloride profile page.

When can VANFLYTA (quizartinib dihydrochloride) generic drug versions launch in South Korea?

Generic name: quizartinib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2027
Generic Entry Controlled by: South Korea Patent 20,080,108,548
Patent Title: IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE

VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.

See drug price trends for VANFLYTA.

The generic ingredient in VANFLYTA is quizartinib dihydrochloride. Additional details are available on the quizartinib dihydrochloride profile page.

When can VANFLYTA (quizartinib dihydrochloride) generic drug versions launch in South Korea?

Generic name: quizartinib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2027
Generic Entry Controlled by: South Korea Patent 20,140,091,619
Patent Title: IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE

VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.

See drug price trends for VANFLYTA.

The generic ingredient in VANFLYTA is quizartinib dihydrochloride. Additional details are available on the quizartinib dihydrochloride profile page.

When can SPRAVATO (esketamine hydrochloride) generic drug versions launch in South Korea?

Generic name: esketamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: South Korea Patent 20,090,029,690
Patent Title: INTRANASAL ADMINISTRATION OF KETAMINE TO TREAT DEPRESSION

Drug Price Trends for SPRAVATO
SPRAVATO is a drug marketed by Janssen Pharms. There are seven patents protecting this drug. There has been litigation on patents covering SPRAVATO

See drug price trends for SPRAVATO.

The generic ingredient in SPRAVATO is esketamine hydrochloride. Additional details are available on the esketamine hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in South Korea?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: South Korea Patent 101,478,593

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in South Korea?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: South Korea Patent 20,090,123,882
Patent Title: PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in South Korea?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: South Korea Patent 20,080,106,564

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in South Korea?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: South Korea Patent 20,090,125,846
Patent Title: SOLID PHARMACEUTICAL COMPOSITION COMPRISING A BENZIMIDAZOLE-7-CARBOXYLATE DERIVATIVE AND A PH CONTROL AGENT

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can INLYTA (axitinib) generic drug versions launch in South Korea?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: South Korea Patent 101,237,588

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can INLYTA (axitinib) generic drug versions launch in South Korea?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: South Korea Patent 20,090,127,949

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in South Korea?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: South Korea Patent 101,475,968

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Korea?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: South Korea Patent 101,475,971

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Korea?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: South Korea Patent 101,537,200

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Korea?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: South Korea Patent 20,100,020,456

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in South Korea?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: South Korea Patent 101,441,365

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in South Korea?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: South Korea Patent 20,090,018,104
Patent Title: ACETYLENIC HETEROARYL COMPOUNDS

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in South Korea?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: South Korea Patent 101,668,973

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in South Korea?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: South Korea Patent 20,150,090,264

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in South Korea?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: South Korea Patent 101,930,588

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in South Korea?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: South Korea Patent 20,100,017,904

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in South Korea?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: South Korea Patent 20,160,002,937

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in South Korea?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: South Korea Patent 101,631,475

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in South Korea?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: South Korea Patent 20,100,023,950

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in South Korea?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: South Korea Patent 101,631,475

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in South Korea?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: South Korea Patent 20,100,023,950

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in South Korea?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: South Korea Patent 101,549,876

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in South Korea?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: South Korea Patent 20,150,036,210

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch in South Korea?

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 101,486,228

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 101,598,402

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 102,061,001

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 20,100,031,512
Patent Title: SYNTHETIC BILE ACID COMPOSITION, METHOD, AND PREPARATION

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 20,130,133,881
Patent Title: SYNTHETIC BILE ACID COMPOSITION, METHOD, AND PREPARATION

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 20,150,013,305
Patent Title: 합성 담즙산 조성물, 방법 및 제조물 (SYNTHETIC BILE ACID COMPOSITION METHOD AND PREPARATION)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 20,160,025,044
Patent Title: 합성 담즙산 조성물, 방법 및 제조물 (SYNTHETIC BILE ACID COMPOSITION, METHOD, AND PREPARATION)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in South Korea?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: South Korea Patent 20,180,061,401
Patent Title: 합성 담즙산 조성물, 방법 및 제조물 (SYNTHETIC BILE ACID COMPOSITION METHOD AND PREPARATION)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can CARDAMYST (etripamil) generic drug versions launch in South Korea?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: South Korea Patent 101,541,557

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can CARDAMYST (etripamil) generic drug versions launch in South Korea?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: South Korea Patent 20,100,043,175
Patent Title: 단기 작용 페닐알킬아민 칼슘 채널 차단제 및 이의 용도 (SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF)

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in South Korea?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: South Korea Patent 20,090,045,233
Patent Title: SHORT-ACTING BENZODIAZEPINE SALTS AND THEIR POLYMORPHIC FORMS

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in South Korea?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: South Korea Patent 20,150,081,370
Patent Title: 속효형 벤조디아제핀 염 및 이의 중합체 형태 (SHORT-ACTING BENZODIAZEPINE SALTS AND THEIR POLYMORPHIC FORMS)

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in South Korea?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: South Korea Patent 20,170,091,770
Patent Title: 속효형 벤조디아제핀 염 및 이의 중합체 형태 (SHORT-ACTING BENZODIAZEPINE SALTS AND THEIR POLYMORPHIC FORMS)

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in South Korea?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: South Korea Patent 101,553,418

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in South Korea?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: South Korea Patent 20,100,050,504
Patent Title: 피리다지논 유도체 (PYRIDAZINONE DERIVATES)

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in South Korea?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: South Korea Patent 101,536,786

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in South Korea?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: South Korea Patent 20,100,036,367
Patent Title: 알로그립틴 및 메트포르민 히드로클로라이드를 포함하는 고체 제제 (SOLID PREPARATION COMPRISING ALOGLIPTIN AND METFORMIN HYDROCHLORIDE)

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can RASUVO (methotrexate) generic drug versions launch in South Korea?

Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: South Korea Patent 101,260,554

Drug Price Trends for RASUVO
RASUVO is a drug marketed by Medexus. There is one patent protecting this drug. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. Additional details are available on the methotrexate profile page.

When can RASUVO (methotrexate) generic drug versions launch in South Korea?

Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: South Korea Patent 20,090,079,876

Drug Price Trends for RASUVO
RASUVO is a drug marketed by Medexus. There is one patent protecting this drug. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. Additional details are available on the methotrexate profile page.

When can MULPLETA (lusutrombopag) generic drug versions launch in South Korea?

Generic name: lusutrombopag
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 31, 2027
Generic Entry Controlled by: South Korea Patent 20,100,027,243

MULPLETA is a drug marketed by Vancocin Italia. There are three patents protecting this drug.

See drug price trends for MULPLETA.

The generic ingredient in MULPLETA is lusutrombopag. Additional details are available on the lusutrombopag profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Korea?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: South Korea Patent 101,632,851

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Korea?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: South Korea Patent 20,140,049,086

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in South Korea?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: South Korea Patent 20,150,008,513

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can WINLEVI (clascoterone) generic drug versions launch in South Korea?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: South Korea Patent 101,495,192

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in South Korea?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: South Korea Patent 20,100,044,845
Patent Title: Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in South Korea?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: South Korea Patent 101,475,189

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can INTRAROSA (prasterone) generic drug versions launch in South Korea?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: South Korea Patent 101,638,130

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in South Korea?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: South Korea Patent 101,680,287

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in South Korea?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: South Korea Patent 20,130,103,805
Patent Title: 폐경기 치료용 DHEA 조성물 (DHEA DHEA COMPOSITIONS FOR TREATING MENOPAUSE)

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in South Korea?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: South Korea Patent 20,100,055,440
Patent Title: 방사성 제약 조성물 (RADIOPHARMACEUTICAL COMPOSITION)

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in South Korea?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: South Korea Patent 101,330,096

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in South Korea?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: South Korea Patent 101,381,263

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in South Korea?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: South Korea Patent 20,100,072,020
Patent Title: PROCESS FOR THE MANUFACTURE OF A PHARMACEUTICAL PRODUCT COMPRISING CITRIC ACID, MAGNESIUM OXIDE, POTASSIUM BICARBONATE AND SODIUM PICOSULFATE, PHARMACEUTICAL COMPOSITION COMPRISING GRANULES OBTAINED BY SUCH PROCESS AND INTERMEDIATE

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can KORSUVA (difelikefalin acetate) generic drug versions launch in South Korea?

Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2027
Generic Entry Controlled by: South Korea Patent 101,513,842

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in South Korea?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: South Korea Patent 101,438,071

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in South Korea?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: South Korea Patent 101,590,115

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in South Korea?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: South Korea Patent 20,100,126,266
Patent Title: PHARMACEUTICAL COMPOSITIONS

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in South Korea?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: South Korea Patent 20,130,030,306
Patent Title: PHARMACEUTICAL COMPOSITIONS

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in South Korea?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: South Korea Patent 101,149,295

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in South Korea?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: South Korea Patent 20,090,087,127

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in South Korea?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: South Korea Patent 101,296,099

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in South Korea?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: South Korea Patent 20,100,110,297
Patent Title: Antibacterial aminoglycoside analogs

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in South Korea?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Korea Patent 101,291,643

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in South Korea?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Korea Patent 101,294,872

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in South Korea?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Korea Patent 101,411,806

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in South Korea?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Korea Patent 20,110,050,708

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in South Korea?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Korea Patent 20,110,050,709

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in South Korea?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Korea Patent 101,291,643

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in South Korea?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Korea Patent 101,294,872

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in South Korea?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Korea Patent 101,411,806

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in South Korea?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Korea Patent 20,110,050,708

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in South Korea?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: South Korea Patent 20,110,050,709

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in South Korea?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: South Korea Patent 101,501,785

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in South Korea?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: South Korea Patent 20,090,096,440
Patent Title: SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in South Korea?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: South Korea Patent 20,100,101,130
Patent Title: SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in South Korea?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: South Korea Patent 20,160,040,745
Patent Title: 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 (SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORENITRAM (treprostinil diolamine) generic drug versions launch in South Korea?

Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2027
Generic Entry Controlled by: South Korea Patent 101,614,465

ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering ORENITRAM

See drug price trends for ORENITRAM.

The generic ingredient in ORENITRAM is treprostinil diolamine. Additional details are available on the treprostinil diolamine profile page.

When can ORENITRAM (treprostinil diolamine) generic drug versions launch in South Korea?

Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2027
Generic Entry Controlled by: South Korea Patent 101,898,407

ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering ORENITRAM

See drug price trends for ORENITRAM.

The generic ingredient in ORENITRAM is treprostinil diolamine. Additional details are available on the treprostinil diolamine profile page.

When can ORENITRAM (treprostinil diolamine) generic drug versions launch in South Korea?

Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2027
Generic Entry Controlled by: South Korea Patent 20,100,105,852
Patent Title: 레모둘린®의 활성 성분인 트레프로스티닐의 개선된 제조 방법 (174; AN IMPROVED PROCESS TO PREPARE TREPROSTINIL THE ACTIVE INGREDIENT IN REMODULIN174;)

ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering ORENITRAM

See drug price trends for ORENITRAM.

The generic ingredient in ORENITRAM is treprostinil diolamine. Additional details are available on the treprostinil diolamine profile page.

When can ORENITRAM (treprostinil diolamine) generic drug versions launch in South Korea?

Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2027
Generic Entry Controlled by: South Korea Patent 20,160,048,222
Patent Title: 레모둘린®의 활성 성분인 트레프로스티닐의 개선된 제조 방법 (AN IMPROVED PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN®)

ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering ORENITRAM

See drug price trends for ORENITRAM.

The generic ingredient in ORENITRAM is treprostinil diolamine. Additional details are available on the treprostinil diolamine profile page.

When can ORENITRAM (treprostinil diolamine) generic drug versions launch in South Korea?

Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2027
Generic Entry Controlled by: South Korea Patent 20,170,081,292
Patent Title: 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법 (? AN IMPROVED PROCESS TO PREPARE TREPROSTINIL THE ACTIVE INGREDIENT IN REMODULIN?)

ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering ORENITRAM

See drug price trends for ORENITRAM.

The generic ingredient in ORENITRAM is treprostinil diolamine. Additional details are available on the treprostinil diolamine profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in South Korea?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: South Korea Patent 102,163,196

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in South Korea?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: South Korea Patent 102,318,070

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in South Korea?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: South Korea Patent 20,100,099,292
Patent Title: DOSING REGIMEN ASSOCIATED WITH LONG ACTING INJECTABLE PALIPERIDONE ESTERS

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in South Korea?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: South Korea Patent 20,190,049,933
Patent Title: 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법 (DOSING REGIMEN ASSOCIATED WITH LONG ACTING INJECTABLE PALIPERIDONE ESTERS)

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in South Korea?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: South Korea Patent 101,451,564

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in South Korea?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: South Korea Patent 101,569,604

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in South Korea?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: South Korea Patent 101,752,080

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in South Korea?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: South Korea Patent 20,150,133,854
Patent Title: 레보도파 방출 제어형 제제 및 이의 용도 (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

South Korea Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risk, and Commercial Outlook

Last updated: October 13, 2026

South Korea is a regulated, reimbursement-driven pharmaceutical market with strong domestic manufacturing, high generic penetration, and an advanced biologics sector. Commercial opportunities are concentrated in oncology, rare diseases, specialty medicines, biosimilars, cell and gene therapies, and contract development and manufacturing. The principal barriers are centralized price control, extensive generic competition, patent-linkage litigation, reimbursement negotiations, local clinical requirements, and manufacturing-quality scrutiny.

What is the size and structure of the South Korean pharmaceutical market?

South Korea has a universal health-insurance system administered through the National Health Insurance Service, with reimbursement and utilization review managed through the Health Insurance Review and Assessment Service. The market combines multinational innovative products, domestic branded generics, low-cost generics, biosimilars, and hospital-distributed specialty medicines.

South Korea is an OECD high-income market with an aging population and rising demand for oncology, immunology, diabetes, cardiovascular, central nervous system, and rare-disease products. Health expenditure reached approximately 9.7% of gross domestic product in 2022, reflecting sustained long-term demand for medical and pharmaceutical products (OECD, 2023).

Market characteristic Commercial effect
Universal health insurance Broad patient access but strong payer control
Centralized reimbursement review Price and indication negotiations are critical
High generic utilization Rapid erosion after patent expiry
Strong domestic manufacturers Competitive local licensing and manufacturing base
Aging population Growth in oncology, dementia, diabetes, cardiovascular and orthopedic drugs
Advanced biologics capability Opportunity for biosimilars, CDMO services and complex injectables
Export-oriented companies Korea can function as both a sales market and regional manufacturing hub

Korean companies include Celltrion, Samsung Biologics, Samsung Bioepis, Hanmi Pharmaceutical, Yuhan, Chong Kun Dang, Daewoong Pharmaceutical, GC Pharma, LG Chem, SK Biopharmaceuticals and HK inno.N. Multinational companies operate through subsidiaries, distributors, local licensees, co-promotion arrangements and direct commercial affiliates.

How do branded and generic drugs compete in South Korea?

The South Korean market has two distinct branded segments:

  1. Innovative products protected by patents, regulatory exclusivity and data protection.
  2. Domestic branded generics marketed under proprietary Korean trade names after generic entry.

Branded generics often compete through physician promotion, hospital formulary access, supply reliability, clinical evidence, lifecycle management and local distribution. Price is important, but hospital purchasing groups and prescribing familiarity also influence market share.

Generic entry is usually rapid once the principal compound patent expires. Competition may involve numerous products with the same active ingredient, dosage and route. This can produce substantial price erosion and marketing fragmentation.

South Korea’s generic pricing system has historically provided higher reimbursement for products meeting specified quality and bioequivalence requirements, while imposing lower prices on products that do not satisfy all criteria. A commonly cited reference point has been a reimbursement price near 53.55% of the originator price for qualifying generics, although pricing rules and implementation criteria have changed over time (Ministry of Health and Welfare, 2020).

The practical effect is a low-price, high-volume market. Companies need efficient manufacturing, reliable supply, strong hospital relationships and disciplined sales spending. A product with regulatory approval but weak distribution is unlikely to achieve material market share.

What regulatory pathway applies to branded and generic drugs?

The Ministry of Food and Drug Safety, or MFDS, regulates drug approval, manufacturing, clinical trials, pharmacovigilance, biologics and post-market compliance.

New drugs

A new drug application generally requires:

  • Quality, chemistry and manufacturing information
  • Nonclinical pharmacology and toxicology
  • Clinical safety and efficacy data
  • Korean or internationally accepted clinical evidence
  • Risk-management information
  • Good manufacturing practice documentation
  • Labeling and prescribing information

MFDS may accept foreign clinical data when the data are scientifically applicable to the Korean population and the application satisfies local requirements. Korean bridging studies may be required where ethnic sensitivity, pharmacokinetics, dosage, safety or disease characteristics create regulatory concerns.

Priority pathways exist for certain products, including innovative treatments, orphan drugs, breakthrough products and products addressing unmet medical needs. Priority review can reduce regulatory timing, but approval does not guarantee reimbursement.

Generic drugs

A generic applicant generally must demonstrate pharmaceutical equivalence and bioequivalence, submit manufacturing and quality documentation, and comply with MFDS requirements for the applicable dosage form.

For complex products, conventional bioequivalence may not be sufficient. Injectable, inhaled, modified-release, transdermal, ophthalmic and locally acting products may require comparative quality, pharmacokinetic, pharmacodynamic or clinical evidence.

South Korea has also tightened scrutiny of bioequivalence and manufacturing documentation following quality and data-integrity controversies. The result is higher compliance risk for manufacturers relying on weak documentation or outsourced production.

Biosimilars

MFDS has established a biosimilar pathway broadly aligned with international scientific principles. Developers must establish similarity through a stepwise package covering:

  • Analytical and structural comparability
  • Functional activity
  • Pharmacokinetics and pharmacodynamics
  • Immunogenicity
  • Comparative clinical evidence where required

South Korea is one of the most important biosimilar development and manufacturing jurisdictions in Asia. Celltrion, Samsung Bioepis and other Korean companies have developed products targeting major biologics, including monoclonal antibodies and oncology therapies.

Biosimilar approval does not automatically create interchangeability in every clinical setting. Substitution, prescribing practice, hospital policy and reimbursement rules remain commercially significant.

What patent protections cover branded drugs in South Korea?

South Korean pharmaceutical patent estates usually include several layers:

Patent category Typical protection
Composition-of-matter patent Active ingredient or molecular structure
Salt, polymorph or crystal patent Specific solid form or chemical form
Formulation patent Release profile, excipients, dosage form or stability
Combination patent Drug used with another active ingredient
Method-of-use patent Treatment of a disease, patient group or biomarker population
Manufacturing patent Synthetic route, purification or biological production process
Device or delivery patent Injector, cartridge, inhaler, patch or delivery system

South Korean patents generally run for 20 years from the relevant filing date, subject to patent-term adjustment and pharmaceutical patent-term extension rules. A patent-term extension may be available for regulatory delay affecting certain pharmaceutical products, subject to statutory limits and eligibility conditions under the Korean Patent Act.

Patent strategy therefore depends on filing chronology. An early composition patent can expire well before later formulation, use or manufacturing patents. Later patents can delay or complicate generic launch, but they may be more vulnerable to invalidity challenges if the claimed improvement lacks inventive step or sufficient technical support.

What is the South Korean equivalent of the Orange Book?

South Korea does not use the U.S. FDA Orange Book system. MFDS administers a patent-information and approval-linkage framework under the Pharmaceutical Affairs Act.

The Korean system allows qualifying patents related to an approved drug to be listed in a patent register. Generic applicants must address listed patents and provide notice to the originator or patent holder when filing an application that may fall within the patent-linkage framework.

The Korean register is narrower in practical operation than the U.S. Orange Book because listing, notice, litigation and sales suspension operate under Korean statutory rules rather than U.S. Hatch-Waxman procedures. Companies should not assume that an Orange Book listing, U.S. Paragraph IV strategy or U.S. patent expiration date produces the same result in South Korea.

How do Paragraph IV challenges work in South Korea?

South Korea has a patent-linkage mechanism that is functionally comparable to parts of the U.S. Paragraph IV system, but the legal process differs.

A generic applicant may challenge a listed patent through invalidation or non-infringement proceedings. Depending on the circumstances, the applicant may obtain a commercial advantage for being an early successful challenger. Korean law also provides mechanisms that can delay generic sales after notice and litigation.

Key features include:

  • Patent listing linked to an approved pharmaceutical product
  • Notice to the originator or patent holder
  • Generic certification concerning patent status
  • Patent invalidation and non-infringement litigation
  • Potential temporary sales suspension
  • Preferential sales rights for certain first challengers
  • Administrative and judicial review by Korean authorities and courts

The commercial value of a challenge depends on whether the patent covers the commercially relevant product, whether the patent is likely to survive invalidation, the number of competing generic applicants and the reimbursement price available after launch.

A generic applicant must also evaluate patent-risk timing. Filing before patent expiry may create a litigation advantage, but an early launch can expose the company to injunction, damages and reputational risk if the patent is upheld.

When do branded drugs lose exclusivity in South Korea?

Loss of exclusivity is determined by a combination of patent expiry, regulatory data protection, patent-term extension, supplementary patents and reimbursement timing.

Exclusivity issue South Korean assessment
Core compound patent Usually the principal barrier to generic approval or launch
Patent-term extension Can extend protection for qualifying pharmaceutical products
Formulation patent May delay a particular dosage form but not necessarily all products
Method-of-use patent May affect labeling, marketing and induced-infringement risk
Data protection Can delay reliance on originator data for certain products
Orphan-drug protection May provide additional regulatory exclusivity
Patent linkage Can create a temporary sales suspension after generic notice
Reimbursement listing May determine whether an approved generic can enter commercially

Generic companies should track Korean patent expiry by jurisdiction rather than relying on U.S., European or Japanese dates. Patent families often have different filing histories, claim scope and term adjustments in Korea.

What formulation and method-of-use patents create the greatest risk?

Formulation patents are particularly relevant where the originator has moved from an immediate-release tablet to an extended-release, fixed-dose, injectable, inhaled or device-based product. These patents can protect commercially important versions even after the active ingredient patent has expired.

Method-of-use patents may cover:

  • A biomarker-defined patient population
  • A second-line or maintenance indication
  • Combination therapy
  • A dosing interval
  • Treatment of a specific disease subtype
  • Reduction of a treatment-related adverse event

Korean courts assess validity and infringement under Korean patent law. A generic that omits a patented indication from its label may reduce risk, but label carving does not eliminate all exposure where prescribing practices, product characteristics or marketing conduct support an infringement theory.

For biologics, manufacturing and process claims can be more important than a single composition patent. Cell-line, culture, purification and formulation claims may create barriers even when the biosimilar has a different production process.

What is the FDA regulatory status of drugs sold in South Korea?

MFDS approval is separate from U.S. FDA approval. A product approved in South Korea does not receive automatic U.S. approval, and U.S. FDA approval does not automatically establish Korean reimbursement or market access.

A Korean company seeking U.S. entry usually needs:

  • A U.S. NDA, ANDA, BLA or applicable pathway
  • FDA-compliant manufacturing
  • U.S.-relevant clinical or bridging evidence
  • Establishment registration and inspection readiness
  • U.S. labeling and pharmacovigilance systems

Conversely, multinational companies can often leverage global clinical packages in Korea, but MFDS may require local bridging evidence or additional analysis. FDA inspection history is commercially valuable but does not replace Korean regulatory review.

Which regulatory opportunities are most attractive?

Biosimilars and complex biologics

South Korea has established scientific expertise, manufacturing capacity and export infrastructure. Opportunities include:

  • Oncology monoclonal antibodies
  • Immunology biologics
  • Insulin and other peptide products
  • Long-acting injectables
  • High-concentration formulations
  • Autoinjector and pen-device combinations
  • Cell and gene therapy manufacturing

Contract development and manufacturing

Korean CDMO companies can support clinical and commercial manufacturing for global sponsors. Demand is strongest for mammalian cell culture, antibody-drug conjugates, sterile injectables, viral vectors and advanced therapies.

Orphan and rare-disease medicines

The aging population and expanding diagnostic capabilities support specialty products with limited patient populations. MFDS orphan-drug procedures can provide regulatory advantages, but reimbursement remains the principal commercial hurdle.

Licensing and co-development

Foreign companies can enter through:

  • Local licensing
  • Joint ventures
  • Co-development
  • Distribution agreements
  • Regional manufacturing
  • Co-promotion with Korean companies

Korean companies have demonstrated willingness to license both inbound and outbound assets. Examples include Yuhan’s licensing relationship with Janssen for lazertinib and the extensive global commercialization partnerships used by Celltrion and Samsung Bioepis (Janssen Biotech, 2018; Johnson & Johnson, 2024).

Digital and decentralized clinical development

South Korea has advanced hospitals, high digital connectivity and concentrated specialist networks. These conditions can support decentralized data collection, electronic patient-reported outcomes, real-world evidence and precision-medicine studies, subject to privacy and clinical-data rules.

What commercial and regulatory challenges face foreign drug companies?

Reimbursement and price pressure

MFDS approval is only the first commercial milestone. The Health Insurance Review and Assessment Service evaluates clinical and economic value, while the National Health Insurance Service negotiates reimbursement conditions. Products may face:

  • Non-reimbursement
  • Restricted indications
  • Price reductions
  • Risk-sharing arrangements
  • Additional evidence requirements
  • Reassessment after launch

High-cost oncology and rare-disease products are especially exposed to budget-impact controls.

Local evidence and hospital access

Although foreign data are usable, local clinical relevance can affect review and reimbursement. University hospitals and tertiary centers are influential in specialty markets. Companies need local medical-affairs infrastructure, key-opinion-leader engagement and post-market evidence generation.

Quality and supply-chain enforcement

MFDS has increased attention to:

  • Data integrity
  • Bioequivalence reliability
  • Nitrosamine and other impurity controls
  • Contract-manufacturer oversight
  • Serialization and traceability
  • Pharmacovigilance
  • Recall readiness

Dependence on imported active pharmaceutical ingredients creates supply and quality risks. Korean authorities may also impose market actions where manufacturing documentation is incomplete or quality systems fail.

Competitive generic density

A generic entrant may face many competing products. The result can be low unit prices, limited margins and substantial sales-force costs. Products with a differentiated formulation, hospital evidence, supply reliability or device advantage generally have stronger economics than undifferentiated oral solids.

Which companies are best positioned in the South Korean market?

Company group Principal strength
Celltrion Biosimilars, biologics commercialization and global expansion
Samsung Biologics Large-scale biologics CDMO
Samsung Bioepis Biosimilar development and global partnerships
Hanmi Pharmaceutical Innovative small molecules, metabolic and oncology programs
Yuhan Domestic commercial base and partnered innovative products
Chong Kun Dang Branded generics, biologics and domestic sales
Daewoong Pharmaceutical Domestic commercial reach and specialty products
GC Pharma Vaccines, plasma products and biologics
SK Biopharmaceuticals Central nervous system and specialty drug development
LG Chem Biologics, specialty pharmaceuticals and platform capabilities

The strongest business models combine regulatory competence with manufacturing scale and payer access. Approval-only strategies are weaker in crowded generic categories.

How strong is the South Korean patent and enforcement environment?

South Korea has a sophisticated patent system, active pharmaceutical litigation and specialized intellectual-property courts. Patent validity and infringement decisions can materially affect launch timing. The country is a member of the WTO and operates within the TRIPS framework, while maintaining its own rules for pharmaceutical patent linkage and regulatory approval.

Patent strength is highest where the estate includes:

  • A valid composition patent with meaningful remaining term
  • Multiple independent formulation or use patents
  • Strong manufacturing claims
  • Consistent global prosecution strategy
  • Clear claim scope covering the marketed product
  • Supporting clinical or technical data

Patent strength is weaker where protection depends on narrow polymorph, dosage or use claims with limited commercial relevance. Generic applicants should conduct Korean claim construction, invalidity and freedom-to-operate analysis rather than relying on foreign litigation outcomes.

What generic launch scenarios exist in South Korea?

Scenario Likely outcome
Core patent expires with no surviving secondary patent Multiple generic launches and rapid price erosion
First generic wins patent challenge Temporary commercial advantage may arise
Formulation patent survives Generic may launch only in a different dosage form
Method-of-use patent survives Label restrictions and infringement risk continue
Patent litigation remains unresolved Delayed launch or launch at risk
Originator has strong hospital contracts Generic approval may not translate into share
Product is a complex biologic Biosimilar entry is slower and evidence-intensive
Reimbursement price is low Only scale-efficient manufacturers remain viable

Key Takeaways

  • South Korea is an attractive but highly controlled pharmaceutical market.
  • MFDS approval does not guarantee reimbursement or commercial access.
  • Generic competition is intense, and price erosion can be rapid after core patent expiry.
  • South Korea has a patent-linkage system but no direct equivalent of the U.S. Orange Book.
  • Paragraph IV-style challenges require Korean-specific patent and regulatory analysis.
  • Formulation, method-of-use, device and manufacturing patents can extend practical market protection.
  • Biosimilars, complex injectables, CDMO services and specialty medicines offer the strongest growth opportunities.
  • Local partnerships can improve reimbursement access, hospital penetration and regulatory execution.
  • Quality systems, bioequivalence documentation and supply-chain controls are material market-entry requirements.
  • Foreign companies should model Korean patent expiry, reimbursement timing, competitor count and hospital adoption together.

FAQs on South Korea’s branded and generic drug market

Is South Korea a reference market for Asian pharmaceutical launches?

South Korea is a high-value reference market with sophisticated regulators, advanced hospitals and strong clinical infrastructure. It is not a substitute for approval in China, Japan, Singapore or other Asian jurisdictions, but Korean regulatory and commercial data can support broader regional strategies.

Does South Korea allow automatic substitution of generics?

Generic substitution is subject to Korean prescribing, dispensing, reimbursement and institutional rules. Hospital formularies and physician prescribing practices can limit substitution even when a generic is approved and reimbursed.

Can a foreign company launch a generic directly in South Korea?

Yes, but the company must satisfy MFDS approval, manufacturing, local representation, pharmacovigilance, reimbursement and distribution requirements. Many foreign companies use a Korean marketing authorization holder, distributor or local licensee.

Are biosimilar prices automatically lower than originator prices?

No. Biosimilar reimbursement depends on Korean pricing rules, product classification, competition, negotiations and reimbursement policy. Approval creates market eligibility but does not establish a uniform commercial price.

What is the largest patent risk for a generic applicant?

The largest risk is usually a surviving patent that covers the actual commercial product or its approved use, combined with patent-linkage litigation and a potential sales suspension. Secondary formulation and method-of-use patents require separate claim-level analysis.

References

  1. Johnson & Johnson. (2024). RYBREVANT plus LAZCLUZE approved by the U.S. FDA for patients with EGFR-mutated non-small cell lung cancer.
  2. Janssen Biotech, Inc. (2018). Janssen and Yuhan Corporation enter license and collaboration agreement for lazertinib.
  3. Ministry of Food and Drug Safety. (2023). Drug approval and review regulations. Republic of Korea.
  4. Ministry of Food and Drug Safety. (2023). Regulations on biological products approval and review. Republic of Korea.
  5. Ministry of Health and Welfare. (2020). Generic drug pricing and quality-based reimbursement policy. Republic of Korea.
  6. Organisation for Economic Co-operation and Development. (2023). Health at a glance 2023: OECD indicators. OECD Publishing.
  7. Republic of Korea. (2023). Pharmaceutical Affairs Act. Korean Law Information Center.
  8. Republic of Korea. (2023). Patent Act. Korean Law Information Center.
  9. Health Insurance Review and Assessment Service. (2023). Drug reimbursement evaluation and pharmaceutical benefit administration. Republic of Korea.
  10. National Health Insurance Service. (2023). National health insurance statistical yearbook. Republic of Korea.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.